Ardea Biosciences Stock Price, News & Analysis (NASDAQ:RDEA)

Previous CloseN/A
Today's RangeN/A
52-Week RangeN/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About Ardea Biosciences (NASDAQ:RDEA)

Ardea Biosciences logoArdea Biosciences, Inc. (Ardea) is a biotechnology company focused on the development of small-molecule therapeutics for the treatment of serious diseases. The Company's product portfolio includes Lesinurad (RDEA594), RDEA3170 and BAY 86-9766 (RDEA119). Lesinurad (RDEA594) is an inhibitor of the URAT1 kidney transporter for the treatment of gout. RDEA3170 is a URAT1 kidney transporter inhibitors for the treatment of gout. BAY 86-9766 (RDEA119) is a MEK inhibitor for the treatment of cancer. On June 19, 2012, AstraZeneca PLC acquired the Company.

Receive RDEA News and Ratings via Email

Sign-up to receive the latest news and ratings for RDEA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:RDEA
CUSIPN/A
Phone+1-858-6526500

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPSN/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

EmployeesN/A
Outstanding SharesN/A

Ardea Biosciences (NASDAQ:RDEA) Frequently Asked Questions

What is Ardea Biosciences' stock symbol?

Ardea Biosciences trades on the NASDAQ under the ticker symbol "RDEA."

Who are some of Ardea Biosciences' key competitors?

How do I buy Ardea Biosciences stock?

Shares of Ardea Biosciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How can I contact Ardea Biosciences?

Ardea Biosciences' mailing address is 4939 Directors Pl, SAN DIEGO, CA 92121-3829, United States. The biotechnology company can be reached via phone at +1-858-6526500.


MarketBeat Community Rating for Ardea Biosciences (RDEA)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  65 (Vote Outperform)
Underperform Votes:  40 (Vote Underperform)
Total Votes:  105
MarketBeat's community ratings are surveys of what our community members think about Ardea Biosciences and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Ardea Biosciences (NASDAQ:RDEA) Analyst Ratings History


No equities research coverage for this company has been tracked by MarketBeat

Earnings

Earnings History for Ardea Biosciences (NASDAQ:RDEA)


No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Ardea Biosciences (NASDAQ:RDEA) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Ardea Biosciences (NASDAQ:RDEA)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Ardea Biosciences (NASDAQ RDEA)

No insider trades for this company have been tracked by MarketBeat.com

Headlines

Ardea Biosciences (NASDAQ RDEA) News Headlines

Source:
No headlines for this company have been tracked by MarketBeat.com

SEC Filings

Ardea Biosciences (NASDAQ:RDEA) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Ardea Biosciences (NASDAQ:RDEA) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Ardea Biosciences (NASDAQ RDEA) Stock Chart for Thursday, December, 14, 2017

Loading chart…

This page was last updated on 12/14/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.